Celleration, Inc., a Eden Prairie, MN-based medical device company focused on developing and commercializing therapeutic ultrasound products, closed an $8m Series E round of equity financing.
Investors include new backer Sightline Healthcare Opportunity Fund, as well as all of the company’s existing institutional shareholders.
As stated by Mark Wagner, President and CEO of Celleration, this financing will enable the company to further grow and develop additional applications for its MIST Therapy® System, which is designed to accelerate healing in wounds by delivering therapeutic, low frequency ultrasound without direct contact of the delivery device to the wound surface.
According to the company, over 45,000 patients have been treated with 800 system installations.
FinSMEs
12/01/2011